Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 AM PST in San Francisco, California. Interested parties can listen to the webcast on the company's website, which will also be archived for replay. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, emphasizing rapid medicine delivery through their signature inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced promising results from the Afrezza with Basal Combination (ABC) Study, presented on November 10, 2022, at the Annual Diabetes Technology Meeting. Technosphere Insulin (TI) demonstrated a faster peak effect, occurring 30 minutes sooner, and significantly reduced postprandial glucose excursions at 60 minutes compared to subcutaneous insulins, with values of 57.9 mg/dL versus 101.4 mg/dL. No severe hypoglycemia was reported, highlighting TI's potential as a pump-sparing option for diabetes patients.
MannKind Corporation (MNKD) reported 3Q 2022 total revenues of $32.8 million, marking a 48% increase compared to 3Q 2021. Afrezza net revenue rose 11% to $10.8 million, with total revenues for the nine-month period reaching $63.7 million. The company experienced a 67% revenue growth in its Endocrine Business Unit, driven by Afrezza and V-Go demand. However, the net loss for 3Q 2022 was $14.4 million, reflecting increased SG&A and interest expenses. Gross profit for Afrezza improved to 81% margin compared to 61%/b% in 2021.
MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 third quarter financial results and year-to-date performance on November 8, 2022, at 9:00 AM ET.
CEO Michael Castagna and CFO Steven Binder will discuss the results during a conference call, accessible via the company's website. MannKind focuses on innovative therapies for endocrine and lung diseases, utilizing advanced inhalation technologies. For further details, visit their official site.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company's webcast presentation will be available on September 28 at 9:00 am ET via its website. Additionally, management will hold virtual one-on-one meetings during the event. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, particularly utilizing advanced dry-powder formulations and inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced the successful completion of a Phase 1 study on clofazimine inhalation suspension (MNKD-101) for treating nontuberculous mycobacterial (NTM) lung disease. The study indicated that the inhalation solution was well tolerated, with no serious adverse events or QT prolongation. The FDA has designated MNKD-101 as an orphan lung and qualified infectious disease product, addressing a high unmet medical need. MannKind plans discussions with the FDA regarding the findings and the ongoing clinical program.
MannKind Corporation (Nasdaq: MNKD) announced CEO Michael Castagna will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:00 PM ET in New York. The company focuses on developing innovative therapeutic products for endocrine and orphan lung diseases. Interested parties can access the live webcast and replay for 14 days via the company’s website. MannKind aims to improve the lives of patients using their advanced inhalation devices and formulations for conditions like diabetes and pulmonary arterial hypertension.
MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $18.9 million for Q2 2022, a 28% increase year-over-year, driven by Afrezza net revenue of $10.6 million. The FDA approved Tyvaso DPI, contributing to revenue recognition. However, collaborations revenue decreased by $7.4 million compared to Q2 2021. The net loss decreased to $29.0 million, or $0.11 per share, from $35.5 million, aided by improved gross profit margins. Expenses rose due to heightened promotional efforts for Afrezza and V-Go.
MannKind Corporation (Nasdaq: MNKD) will announce its 2022 second-quarter financial results on August 9, 2022, at 5:00 PM Eastern Time. CEO Michael Castagna and CFO Steven Binder will lead a conference call to discuss these results and the company's updates. MannKind focuses on developing innovative therapies, particularly for conditions like diabetes and pulmonary arterial hypertension, leveraging its specialized dry-powder delivery technology. Investors can access the live call through the company’s website for detailed insights on performance and strategy.
MannKind Corporation (Nasdaq: MNKD) announced its participation in the BTIG Biotechnology Conference on August 8-9, 2022. CEO Michael Castagna and CFO Steven Binder will engage in one-on-one meetings during this event, aimed at institutional investors.
BTIG specializes in various financial services and hosts client events across multiple sectors. MannKind is known for its innovative products for endocrine and lung diseases, notably Afrezza (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting insulin approved in the U.S. This participation highlights MannKind’s ongoing commitment to advancing its therapeutic portfolio.